Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
167 hedge funds and large institutions have $3.12B invested in Intercept Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 68 increasing their positions, 47 reducing their positions, and 49 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 47
3% less funds holding
Funds holding: 172 → 167 (-5)
10% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 49
24% less capital invested
Capital invested by funds: $4.11B → $3.12B (-$987M)
57% less call options, than puts
Call options by funds: $98.8M | Put options by funds: $231M
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$264M |
| 2 |
Jennison Associates
New York
|
+$76.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$74.5M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$55.1M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$53.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$84.5M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$70.6M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$65.1M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$58M |
| 5 |
VAM
Visium Asset Management
New York
|
-$33M |
ICPT Hedge Fund Activity: Q2 2014 in Review
167 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2014, worth a combined $3.12B — down 24% from $4.11B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of ICPT and 44 opened new positions — a net loss of 5 holders — while 47 trimmed existing stakes and 68 added.
The largest buyer was Carmignac Gestion, opening a new position worth an estimated $264M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $84.5M sold.
- 167 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2014, down from 172 in Q1 2014.
- Funds reported $3.12B of Intercept Pharmaceuticals, Inc. stock for Q2 2014, down 24% quarter-over-quarter.
- 44 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2014 and 49 closed out, a net change of -5 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2014 was Carmignac Gestion, an estimated $264M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q2 2014 was Baker Bros. Advisors, an estimated $84.5M sold.
Based on aggregated 13F filings for Q2 2014.